Cadrenal Therapeutics, Inc. (CVKD)
(Delayed Data from NSDQ)
$10.70 USD
+2.38 (28.61%)
Updated Sep 12, 2024 03:57 PM ET
After-Market: $10.70 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMCadrenal Therapeutics, Inc. (CVKD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$52.47 | $59.97 | $44.98 | 530.65% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Cadrenal Therapeutics, Inc. comes to $52.47. The forecasts range from a low of $44.98 to a high of $59.97. The average price target represents an increase of 530.65% from the last closing price of $8.32.
Analyst Price Targets (2 )
Broker Rating
Cadrenal Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, two are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/13/2024 | Noble Financial | Robert Leboyer | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 2 |
Average Target Price | $52.47 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -1.65 |
CVKD FAQs
Cadrenal Therapeutics, Inc. (CVKD) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Cadrenal Therapeutics, Inc. (CVKD) is $52.47. The current on short-term price targets is based on 2 reports.
The forecasts for Cadrenal Therapeutics, Inc. (CVKD) range from a low of $44.977 to a high of $59.97. The average price target represents a increase of $390.37 from the last closing price of $10.70.
The current UPSIDE for Cadrenal Therapeutics, Inc. (CVKD) is 390.37%
Based on short-term price targets offered by two analysts, the average price target for Cadrenal Therapeutics, Inc. comes to $52.47. The forecasts range from a low of $44.98 to a high of $59.97. The average price target represents an increase of 530.65% from the last closing price of $8.32.